soul trial oral semaglutide cardiovascular outcomes 2024 nejm 📌 Most viewed this week from JAMA: In patients with cardiometabolic #HFpEF, #semaglutide and #tirzepatide reduced the risk of hospitalization for heart failure or all-cause mortality vs sitagliptin, but tirzepatide offered no Optimal Medical Therapy Targeting Metabolic

How do we know fiber-derived short-chain fatty acids boost GLP-1 in the first place

As a result, L-Glutathione can contribute to a clearer, more radiant complexion and may help support the reduction of skin discolouration

Tirzepatide cardiovascular outcome trials are ongoing

this was followed by approval of vildagliptin, alogliptin, saxagliptin and lingaliptin [37]

Cell Mol Life Sci 67:35493555 Libby P, Plutzky J (2007) Inflammation in diabetes mellitus: role of peroxisome proliferator-activated receptor- and peroxisome proliferator-activated receptor- agonists

This is especially important for men managing busy lifestyles who want reliable results without guesswork